Sol-Gel Technologies (SLGL) Receivables (2017 - 2025)
Sol-Gel Technologies (SLGL) reported Receivables of $2.0 million for Q4 2025, down 45.26% year-over-year from $3.6 million in Q4 2024, and down 80.01% on a QoQ basis from $9.8 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 9 years of Receivables data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Receivables fell 45.26% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 45.26% YoY) and the FY2025 annual result came in at $2.0 million, down 45.26% from the prior year.
- Receivables declined to $2.0 million in Q4 2025 per SLGL's latest filing, from $9.8 million in the prior quarter.
- Across five years, Receivables topped out at $13.1 million in Q4 2021 and bottomed at -$5.7 million in Q2 2024.
- The 5-year median for Receivables is $3.6 million (2024), against an average of $4.1 million.
- The widest annual swing landed in 2022, when Receivables tumbled 99.53%; it then jumped 853.58% in 2024.
- Tracing SLGL's Receivables over 5 years: stood at $13.1 million in 2021, then plunged by 99.53% to $62000.0 in 2022, then surged by 508.06% to $377000.0 in 2023, then jumped by 853.58% to $3.6 million in 2024, then tumbled by 45.26% to $2.0 million in 2025.
- Per Business Quant, the three latest SLGL Receivables figures stand at $2.0 million (Q4 2025), $9.8 million (Q3 2025), and $10.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Mar 31, 2025 | 3.88 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Sep 30, 2024 | 7.02 Mn |
| Jun 30, 2024 | -5.68 Mn |
| Mar 31, 2024 | 869,000.00 |
| Dec 31, 2023 | 377,000.00 |
| Dec 31, 2022 | 62,000.00 |
| Dec 31, 2021 | 13.07 Mn |
| Dec 31, 2020 | 2.15 Mn |
| Jun 30, 2020 | 2.95 Mn |
| Dec 31, 2019 | 4.12 Mn |
| Jun 30, 2019 | -7.83 Mn |
| Mar 31, 2019 | 6.35 Mn |
| Dec 31, 2018 | 1.43 Mn |
| Dec 31, 2017 | 1.43 Mn |